Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
The Current Development of Flavivirus Vaccines, Diseases Control and Epidemiological...
share announcement

The Current Development of Flavivirus Vaccines, Diseases Control and Epidemiological Situation

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Tropical and other Infectious Diseases".

Deadline for manuscript submissions: closed (31 March 2025) | Viewed by 578

Special Issue Editors

Dr. Satoru Arai

E-Mail
Guest Editor
Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan
Interests: Japanese encephalitis vaccine; arbovirus infection; virus evolution; seroepidemiological survey; host-virus cophylogeny; zoonotic diseases
Prof. Dr. Tsutomu Omatsu

E-Mail Website
Guest Editor
Center for Infectious Disease Epidemiology and Prevention Research, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Tokyo 183-8509, Japan
Interests: zoonoses; vaccine development; vaccine against dengue virus; vaccine against Japanese encephalitis virus

Special Issue Information

Dear Colleagues,

The Flavivirus genus consists of viruses that can cause serious diseases, such as Dengue, Zika, West Nile, yellow fever, Japanese encephalitis, and tick-borne encephalitis. This Special Issue focuses on sharing the latest developments and vaccine trends in Flavivirus infection. We welcome your original research articles, reviews, and perspectives on novel experimental vaccine candidates, vaccine strategies, immune responses, and concerns or optimizations related to vaccine strategies. We also welcome related topics on the epidemiological situation and trends of Flavivirus infection.

Dr. Satoru Arai
Prof. Dr. Tsutomu Omatsu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • novel vaccine candidates
  • vaccine development
  • vaccination
  • emerging infectious diseases
  • vaccine efficacy
  • vaccination strategies
  • immunization strategies and public health

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

8 pages, 295 KiB  
Brief Report
A Single Dose of Yellow Fever Vaccine Provides Long-Term Immunity in Japanese Travelers
by Shinji Fukushima, Chang Kweng Lim and Atsuo Hamada
Vaccines 2025, 13(7), 675; https://doi.org/10.3390/vaccines13070675 - 24 Jun 2025
Abstract
Yellow fever (YF) is an acute hemorrhagic zoonotic disease that causes severe liver damage, renal failure, and hemorrhagic shock. No antiviral treatment is available; thus, vaccination is a critical preventive measure. Although the World Health Organization (WHO) revised the guidelines regarding the need [...] Read more.
Yellow fever (YF) is an acute hemorrhagic zoonotic disease that causes severe liver damage, renal failure, and hemorrhagic shock. No antiviral treatment is available; thus, vaccination is a critical preventive measure. Although the World Health Organization (WHO) revised the guidelines regarding the need for booster vaccination for YF with the rationale that a single vaccination provides sufficient long-term immunogenicity, no studies have evaluated long-term immunity in Japanese adults who received a single dose of YF vaccine. This study evaluated the long-term persistence of immunogenicity in Japanese adults vaccinated with the YF vaccine. This observational study enrolled Japanese adults who received a single YF vaccination >5 years previously. Blood samples were collected after confirming eligibility for the study. The serum levels of anti-yellow fever virus (YFV)-neutralizing antibodies were measured using the 50% plaque reduction neutralization test (PRNT50). The 65 participants comprised 35 males and 30 females, with a median age at vaccination of 34 years. The time between YF vaccination and registration was between 5 and 26 years. All participants remained seropositive even after a long time. Statistical analysis showed no correlation between the time elapsed since YF vaccination and PRNT50. Our results indicate that a single dose of YF vaccine provides adequate long-term immunity in Japanese adults and that booster vaccinations are not routinely required. These findings strongly aid in the development of travel medicine guidelines and the optimization of vaccination strategies by reducing the usage of medical resources and simplifying the health requirements for travelers. Full article
(This article belongs to the Special Issue The Current Development of Flavivirus Vaccines, Diseases Control and Epidemiological Situation)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop